Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Barnet Delaney Perkins Eye Center, Phoenix, Arizona California Retina Consultants, Oxnard, California Retinal Consultants Medical Group, Sacramento, California Colorado Retina Associates, Lakewood, Colorado Rand Eye Institute, Deerfield Beach, Florida Retina Vitreous Consultants, LLP DBA Retina Group of Florida, Fort Lauderdale, Florida Vitreo Retinal Associates, Gainesville, Florida Florida Eye Associates, Melbourne, Florida Retinal Specialty Institute, Pensacola, Florida Retina Vitreous Associates of Florida, Tampa, Florida University Retina and Macula Associates, Oak Forest, Illinois Retina Partners Midwest, Carmel, Indiana Cumberland Valley Retina Consultants, Hagerstown, Maryland Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center, Boston, Massachusetts Sierra Eye Associates, Reno, Nevada Western Carolina Retinal Associates, Asheville, North Carolina Verum Research, LLC, Eugene, Oregon Mid Atlantic Retina, Bethlehem, Pennsylvania Palmetto Retina Center, LLC, West Columbia, South Carolina Tennessee Retina, Nashville, Tennessee Austin Clinical Research, Austin, Texas Valley Retina Institute, PA, McAllen, Texas Retina Consultants of Texas, The Woodlands, Texas Pacific Northwest Retina LLC, Bellevue, Washington Puerto Rico
Emanuelli Research and Development Center, LLC, Arecibo, Puerto Rico